| Variable . | All participants (n = 71) . | Adalimumab induction only/placebo (n = 31) . | Adalimumab (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 36.6 (11.1) | 36.6 (11.5) | 36.6 (11.0) |
| Male, n (%) | 29 (40.9) | 13 (41.9) | 16 (40.0) |
| Body mass index, mean (SD) | 24.7 (4.9) | 24.5 (4.8) | 24.9 (5.0) |
| Caucasian, n (%) | 70 (98.6) | 31 (100.0) | 39 (97.5) |
| Prior anti-TNF-α exposure, n (%) | 33 (46.5) | 15 (48.4) | 18 (45.0) |
| Concomitant immunomodulator use, n (%) | 26 (36.6) | 12 (38.7) | 14 (35.0) |
| Concomitant corticosteroid use, n (%) | 11 (15.5) | 9 (29.0) | 2 (5.0) |
| Disease duration, mean (SD) | 10.9 (9.2) | 10.5 (9.8) | 11.3 (8.9) |
| Baseline ileal ulcer size as per SES-CD score, n (%) | |||
| Small | 21 (29.6) | 11 (35.5) | 10 (25.0) |
| Medium | 39 (54.9) | 15 (48.4) | 24 (60.0) |
| Large | 11 (15.5) | 5 (16.1) | 6 (15.0) |
| Disease location, n (%) | |||
| Isolated ileal | 52 (73.2) | 25 (80.7) | 27 (67.5) |
| Ileocolonic | 19 (26.8) | 6 (19.4) | 13 (32.5) |
| Baseline hemoglobin (g/L), mean (SD) | 132.6 (15.3) | 134.4 (15.4) | 131.2 (15.3) |
| Baseline C-reactive protein (g/L), mean (SD) | 18.7 (22.4) | 18.7 (26.0) | 18.8 (19.4) |
| Baseline CDAI score, mean (SD) | 316.4 (62.3) | 307.4 (55.3) | 323.4 (67.1) |
| Baseline SES-CD score, mean (SD) | 15.8 (9.2) | 15.8 (9.3) | 15.8 (9.3) |
| Baseline SES-CD score in ileum, mean (SD) | 6.5 (2.2) | 6.1 (2.3) | 6.8 (2.1) |
| Baseline ileum GHAS score, mean (SD) | 5.7 (3.2) | 5.9 (3.5) | 5.6 (3.0) |
| Baseline ileum GHAS score of 0, n (%) | 10 (14.1) | 4 (12.9) | 6 (15.0) |
| Variable . | All participants (n = 71) . | Adalimumab induction only/placebo (n = 31) . | Adalimumab (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 36.6 (11.1) | 36.6 (11.5) | 36.6 (11.0) |
| Male, n (%) | 29 (40.9) | 13 (41.9) | 16 (40.0) |
| Body mass index, mean (SD) | 24.7 (4.9) | 24.5 (4.8) | 24.9 (5.0) |
| Caucasian, n (%) | 70 (98.6) | 31 (100.0) | 39 (97.5) |
| Prior anti-TNF-α exposure, n (%) | 33 (46.5) | 15 (48.4) | 18 (45.0) |
| Concomitant immunomodulator use, n (%) | 26 (36.6) | 12 (38.7) | 14 (35.0) |
| Concomitant corticosteroid use, n (%) | 11 (15.5) | 9 (29.0) | 2 (5.0) |
| Disease duration, mean (SD) | 10.9 (9.2) | 10.5 (9.8) | 11.3 (8.9) |
| Baseline ileal ulcer size as per SES-CD score, n (%) | |||
| Small | 21 (29.6) | 11 (35.5) | 10 (25.0) |
| Medium | 39 (54.9) | 15 (48.4) | 24 (60.0) |
| Large | 11 (15.5) | 5 (16.1) | 6 (15.0) |
| Disease location, n (%) | |||
| Isolated ileal | 52 (73.2) | 25 (80.7) | 27 (67.5) |
| Ileocolonic | 19 (26.8) | 6 (19.4) | 13 (32.5) |
| Baseline hemoglobin (g/L), mean (SD) | 132.6 (15.3) | 134.4 (15.4) | 131.2 (15.3) |
| Baseline C-reactive protein (g/L), mean (SD) | 18.7 (22.4) | 18.7 (26.0) | 18.8 (19.4) |
| Baseline CDAI score, mean (SD) | 316.4 (62.3) | 307.4 (55.3) | 323.4 (67.1) |
| Baseline SES-CD score, mean (SD) | 15.8 (9.2) | 15.8 (9.3) | 15.8 (9.3) |
| Baseline SES-CD score in ileum, mean (SD) | 6.5 (2.2) | 6.1 (2.3) | 6.8 (2.1) |
| Baseline ileum GHAS score, mean (SD) | 5.7 (3.2) | 5.9 (3.5) | 5.6 (3.0) |
| Baseline ileum GHAS score of 0, n (%) | 10 (14.1) | 4 (12.9) | 6 (15.0) |
| Variable . | All participants (n = 71) . | Adalimumab induction only/placebo (n = 31) . | Adalimumab (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 36.6 (11.1) | 36.6 (11.5) | 36.6 (11.0) |
| Male, n (%) | 29 (40.9) | 13 (41.9) | 16 (40.0) |
| Body mass index, mean (SD) | 24.7 (4.9) | 24.5 (4.8) | 24.9 (5.0) |
| Caucasian, n (%) | 70 (98.6) | 31 (100.0) | 39 (97.5) |
| Prior anti-TNF-α exposure, n (%) | 33 (46.5) | 15 (48.4) | 18 (45.0) |
| Concomitant immunomodulator use, n (%) | 26 (36.6) | 12 (38.7) | 14 (35.0) |
| Concomitant corticosteroid use, n (%) | 11 (15.5) | 9 (29.0) | 2 (5.0) |
| Disease duration, mean (SD) | 10.9 (9.2) | 10.5 (9.8) | 11.3 (8.9) |
| Baseline ileal ulcer size as per SES-CD score, n (%) | |||
| Small | 21 (29.6) | 11 (35.5) | 10 (25.0) |
| Medium | 39 (54.9) | 15 (48.4) | 24 (60.0) |
| Large | 11 (15.5) | 5 (16.1) | 6 (15.0) |
| Disease location, n (%) | |||
| Isolated ileal | 52 (73.2) | 25 (80.7) | 27 (67.5) |
| Ileocolonic | 19 (26.8) | 6 (19.4) | 13 (32.5) |
| Baseline hemoglobin (g/L), mean (SD) | 132.6 (15.3) | 134.4 (15.4) | 131.2 (15.3) |
| Baseline C-reactive protein (g/L), mean (SD) | 18.7 (22.4) | 18.7 (26.0) | 18.8 (19.4) |
| Baseline CDAI score, mean (SD) | 316.4 (62.3) | 307.4 (55.3) | 323.4 (67.1) |
| Baseline SES-CD score, mean (SD) | 15.8 (9.2) | 15.8 (9.3) | 15.8 (9.3) |
| Baseline SES-CD score in ileum, mean (SD) | 6.5 (2.2) | 6.1 (2.3) | 6.8 (2.1) |
| Baseline ileum GHAS score, mean (SD) | 5.7 (3.2) | 5.9 (3.5) | 5.6 (3.0) |
| Baseline ileum GHAS score of 0, n (%) | 10 (14.1) | 4 (12.9) | 6 (15.0) |
| Variable . | All participants (n = 71) . | Adalimumab induction only/placebo (n = 31) . | Adalimumab (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 36.6 (11.1) | 36.6 (11.5) | 36.6 (11.0) |
| Male, n (%) | 29 (40.9) | 13 (41.9) | 16 (40.0) |
| Body mass index, mean (SD) | 24.7 (4.9) | 24.5 (4.8) | 24.9 (5.0) |
| Caucasian, n (%) | 70 (98.6) | 31 (100.0) | 39 (97.5) |
| Prior anti-TNF-α exposure, n (%) | 33 (46.5) | 15 (48.4) | 18 (45.0) |
| Concomitant immunomodulator use, n (%) | 26 (36.6) | 12 (38.7) | 14 (35.0) |
| Concomitant corticosteroid use, n (%) | 11 (15.5) | 9 (29.0) | 2 (5.0) |
| Disease duration, mean (SD) | 10.9 (9.2) | 10.5 (9.8) | 11.3 (8.9) |
| Baseline ileal ulcer size as per SES-CD score, n (%) | |||
| Small | 21 (29.6) | 11 (35.5) | 10 (25.0) |
| Medium | 39 (54.9) | 15 (48.4) | 24 (60.0) |
| Large | 11 (15.5) | 5 (16.1) | 6 (15.0) |
| Disease location, n (%) | |||
| Isolated ileal | 52 (73.2) | 25 (80.7) | 27 (67.5) |
| Ileocolonic | 19 (26.8) | 6 (19.4) | 13 (32.5) |
| Baseline hemoglobin (g/L), mean (SD) | 132.6 (15.3) | 134.4 (15.4) | 131.2 (15.3) |
| Baseline C-reactive protein (g/L), mean (SD) | 18.7 (22.4) | 18.7 (26.0) | 18.8 (19.4) |
| Baseline CDAI score, mean (SD) | 316.4 (62.3) | 307.4 (55.3) | 323.4 (67.1) |
| Baseline SES-CD score, mean (SD) | 15.8 (9.2) | 15.8 (9.3) | 15.8 (9.3) |
| Baseline SES-CD score in ileum, mean (SD) | 6.5 (2.2) | 6.1 (2.3) | 6.8 (2.1) |
| Baseline ileum GHAS score, mean (SD) | 5.7 (3.2) | 5.9 (3.5) | 5.6 (3.0) |
| Baseline ileum GHAS score of 0, n (%) | 10 (14.1) | 4 (12.9) | 6 (15.0) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
